<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Signaling by RAS mutants" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Members of the RAS gene family were the first oncogenes to be identified, and mutations in RAS are present in ~20-30% of human cancers (reviewed in Prior et al, 2012). Mutations in the KRAS gene are the most prevalent, and are found with high frequency in colorectal cancer, non-small cell lung cancer and pancreatic cancer, among others. The reasons for the lower prevalence of HRAS and NRAS mutations in human cancers are not fully understood, but may reflect gene-specific functions as well as differential codon usage and spatio-temporal regulation (reviewed in Prior et al, 2012; Stephen et al, 2014; Pylayeva-Gupta et al, 2011). Activating RAS mutations contribute to cellular proliferation, transformation and survival by activating the MAPK signaling pathway, the AKT pathway and the RAL GDS pathway, among others (reviewed in Stephen et al, 2014; Pylayeva-Gupta et al, 2011).&lt;br&gt;&lt;br&gt;Although the frequency and distribution varies between RAS genes and cancer types, the vast majority of activating RAS mutations occur at one of three residues - G12, G13 and Q61. Mutations at these sites favour the RAS:GTP bound form and yield constitutively active versions of the protein (reviewed in Prior et al, 2012).
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=6802949 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 6802949</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Rothfels, Karen</Comment>
  <BiopaxRef>d28</BiopaxRef>
  <BiopaxRef>a89</BiopaxRef>
  <BiopaxRef>fc6</BiopaxRef>
  <Attribute Key="reactome_id" Value="6802949" />
  <Graphics BoardWidth="544.0" BoardHeight="201.0" />
  <DataNode TextLabel="RAS GTPase cycle&#xA;mutants" GraphId="a49e3" Type="Pathway">
    <Comment Source="Reactome">RAS proteins cycle between an active GTP-bound state and an inactive GDP-bound state. GTPase activating proteins (GAPs) stimulate the low intrinsic GTPase activity of RAS proteins, converting the active to the inactive form, while guanine nucleotide exchange factors (GEFs) stimulate the intrinsic dissociation of GDP, allowing its replacement with GTP and consequent activation of RAS.
Disease-causing mutations in RAS promote constitutive signaling by favouring the accumulation of RAS:GTP. The vast majority of these mutations are loss of function mutations at G12, G13 and Q61. These mutations disrupt the GTPase activity of RAS proteins by interfering with nucleophilic attack on the gamma phosphate of GTP. A smaller proportion of RAS mutations increase the intrinsic GDP dissociation rate, while other mutations interfere with RAS interactions with GAPs (reviewed in Prior et al, 2012; Pylayeva-Gupta et al, 2011; Stephen et al, 2014; Samatar and Poulikakos, 2014).</Comment>
    <BiopaxRef>d28</BiopaxRef>
    <BiopaxRef>fc6</BiopaxRef>
    <BiopaxRef>a89</BiopaxRef>
    <BiopaxRef>ba6</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="204.5" CenterY="127.0" Width="141.0" Height="72.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9649913" />
  </DataNode>
  <DataNode TextLabel="Signaling downstream&#xA;of RAS mutants" GraphId="c9fd6" Type="Pathway">
    <Comment Source="Reactome">Disease-causing mutations in RAS favour the active RAS:GTP bound form and yield constitutively active forms of the protein (reviewed in Prior et al, 2011; Maertens and Cichowski, 2014).  Mutations in RAS contribute to cellular proliferation, transformation and survival by activating the MAPK signaling pathway, the AKT pathway and the RAL GDS pathway, among others (reviewed in Stephen et al, 2014; Pylayeva-Gupta et al, 2011)</Comment>
    <BiopaxRef>d28</BiopaxRef>
    <BiopaxRef>e54</BiopaxRef>
    <BiopaxRef>a89</BiopaxRef>
    <BiopaxRef>fc6</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="406.5" CenterY="128.5" Width="215.0" Height="85.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9649948" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d28">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22589270</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A comprehensive survey of Ras mutations in cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prior IA, Lewis PD, Mattos C.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a89">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24651010</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dragging ras back in the ring.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stephen AG, Esposito D, Bagni RK, McCormick F.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fc6">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21993244</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAS oncogenes: weaving a tumorigenic web.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pylayeva-Gupta Y, Grabocka E, Grabocka E, Bar-Sagi D.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ba6">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25435214</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Targeting RAS-ERK signalling in cancer: promises and challenges.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Samatar AA, Poulikakos PI.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e54">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24814062</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Maertens O, Cichowski K.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

